Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Novel activities of safe-in-human broad-spectrum antiviral agents.

Ianevski A, Zusinaite E, Kuivanen S, Strand M, Lysvand H, Teppor M, Kakkola L, Paavilainen H, Laajala M, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Bjørås M, Nordbø SA, Dumpis U, Vitkauskiene A, Öhrmalm C, Bondeson K, Bergqvist A, Aittokallio T, Cox RJ, Evander M, Hukkanen V, Marjomaki V, Julkunen I, Vapalahti O, Tenson T, Merits A, Kainov D.

Antiviral Res. 2018 Jun;154:174-182. doi: 10.1016/j.antiviral.2018.04.016. Epub 2018 Apr 23. Review.

PMID:
29698664
2.

Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins.

Bulanova D, Ianevski A, Bugai A, Akimov Y, Kuivanen S, Paavilainen H, Kakkola L, Nandania J, Turunen L, Ohman T, Ala-Hongisto H, Pesonen HM, Kuisma MS, Honkimaa A, Walton EL, Oksenych V, Lorey MB, Guschin D, Shim J, Kim J, Than TT, Chang SY, Hukkanen V, Kulesskiy E, Marjomaki VS, Julkunen I, Nyman TA, Matikainen S, Saarela JS, Sane F, Hober D, Gabriel G, De Brabander JK, Martikainen M, Windisch MP, Min JY, Bruzzone R, Aittokallio T, Vähä-Koskela M, Vapalahti O, Pulk A, Velagapudi V, Kainov DE.

Viruses. 2017 Sep 25;9(10). pii: E271. doi: 10.3390/v9100271.

3.

Ebolavirus protein VP24 interferes with innate immune responses by inhibiting interferon-λ1 gene expression.

He F, Melén K, Maljanen S, Lundberg R, Jiang M, Österlund P, Kakkola L, Julkunen I.

Virology. 2017 Sep;509:23-34. doi: 10.1016/j.virol.2017.06.002. Epub 2017 Jun 5.

4.

Production, purification and immunogenicity of recombinant Ebola virus proteins - A comparison of Freund's adjuvant and adjuvant system 03.

Melén K, Kakkola L, He F, Airenne K, Vapalahti O, Karlberg H, Mirazimi A, Julkunen I.

J Virol Methods. 2017 Apr;242:35-45. doi: 10.1016/j.jviromet.2016.12.014. Epub 2016 Dec 24.

PMID:
28025125
5.

Protein profiling of nasopharyngeal aspirates of hospitalized and outpatients revealed cytokines associated with severe influenza A(H1N1)pdm09 virus infections: A pilot study.

Fu Y, Gaelings L, Jalovaara P, Kakkola L, Kinnunen MT, Kallio-Kokko H, Valkonen M, Kantele A, Kainov DE.

Cytokine. 2016 Oct;86:10-14. doi: 10.1016/j.cyto.2016.07.003. Epub 2016 Jul 18.

PMID:
27442005
6.

Prospective clinical and serological follow-up in early childhood reveals a high rate of subclinical RSV infection and a relatively high reinfection rate within the first 3 years of life.

Kutsaya A, Teros-Jaakkola T, Kakkola L, Toivonen L, Peltola V, Waris M, Julkunen I.

Epidemiol Infect. 2016 Jun;144(8):1622-33. doi: 10.1017/S0950268815003143. Epub 2016 Jan 6.

PMID:
26732801
7.

Comparative Analysis of Whole-Genome Sequences of Influenza A(H1N1)pdm09 Viruses Isolated from Hospitalized and Nonhospitalized Patients Identifies Missense Mutations That Might Be Associated with Patient Hospital Admissions in Finland during 2009 to 2014.

Mishel P, Ojala T, Benner C, Lakspere T, Bychkov D, Jalovaara P, Kakkola L, Kallio-Kokko H, Kantele A, Kankainen M, Ikonen N, Ripatti S, Julkunen I, Kainov DE.

Genome Announc. 2015 Jul 30;3(4). pii: e00676-15. doi: 10.1128/genomeA.00676-15.

8.

Complete Genome Sequences of Influenza A/H1N1 Strains Isolated from Patients during the 2013-2014 Epidemic Season in Finland.

Jalovaara P, Mishel P, Kallio-Kokko H, Valkonen M, Kantele A, Ikonen N, Julkunen I, Kakkola L, Kutsaya A, Vuorinen T, Mattila P, Almusa H, Kainov D.

Genome Announc. 2015 Mar 12;3(2). pii: e01523-14. doi: 10.1128/genomeA.01523-14.

9.

Full-Genome Sequences of Influenza H3N2 Virus Strains Isolated from Finnish Patients during the 2012-2013 Epidemic Season.

Lakspere T, Kallio-Kokko H, Kantele A, Mattila P, Almusa H, Kainov D, Kakkola L.

Genome Announc. 2014 Mar 27;2(2). pii: e00039-14. doi: 10.1128/genomeA.00039-14.

10.

Full-Genome Sequences of Influenza A(H1N1)pdm09 Viruses Isolated from Finnish Patients from 2009 to 2013.

Lakspere T, Tynell J, Kaloinen M, Vanlede M, Parsons A, Ikonen N, Kallio-Kokko H, Kantele A, Mattila P, Almusa H, Julkunen I, Kainov D, Kakkola L.

Genome Announc. 2014 Jan 16;2(1). pii: e01004-13. doi: 10.1128/genomeA.01004-13.

11.

Inhibition of influenza A virus infection in vitro by saliphenylhalamide-loaded porous silicon nanoparticles.

Bimbo LM, Denisova OV, Mäkilä E, Kaasalainen M, De Brabander JK, Hirvonen J, Salonen J, Kakkola L, Kainov D, Santos HA.

ACS Nano. 2013 Aug 27;7(8):6884-93. doi: 10.1021/nn402062f. Epub 2013 Aug 1.

PMID:
23889734
12.

Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice.

Kakkola L, Denisova OV, Tynell J, Viiliäinen J, Ysenbaert T, Matos RC, Nagaraj A, Ohman T, Kuivanen S, Paavilainen H, Feng L, Yadav B, Julkunen I, Vapalahti O, Hukkanen V, Stenman J, Aittokallio T, Verschuren EW, Ojala PM, Nyman T, Saelens X, Dzeyk K, Kainov DE.

Cell Death Dis. 2013 Jul 25;4:e742. doi: 10.1038/cddis.2013.267.

13.

Molecular evolution and epidemiology of echovirus 6 in Finland.

Smura T, Kakkola L, Blomqvist S, Klemola P, Parsons A, Kallio-Kokko H, Savolainen-Kopra C, Kainov DE, Roivainen M.

Infect Genet Evol. 2013 Jun;16:234-47. doi: 10.1016/j.meegid.2013.02.011. Epub 2013 Feb 24.

PMID:
23462388
14.

Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection.

Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J, Yadav B, Aittokallio T, Kaukinen P, Ahola T, Kuivanen S, Vapalahti O, Kantele A, Tynell J, Julkunen I, Kallio-Kokko H, Paavilainen H, Hukkanen V, Elliott RM, De Brabander JK, Saelens X, Kainov DE.

J Biol Chem. 2012 Oct 12;287(42):35324-32. doi: 10.1074/jbc.M112.392142. Epub 2012 Aug 21.

15.

Emerging cellular targets for influenza antiviral agents.

Müller KH, Kakkola L, Nagaraj AS, Cheltsov AV, Anastasina M, Kainov DE.

Trends Pharmacol Sci. 2012 Feb;33(2):89-99. doi: 10.1016/j.tips.2011.10.004. Epub 2011 Dec 22. Review.

PMID:
22196854
16.

Replication of and protein synthesis by TT viruses.

Kakkola L, Hedman K, Qiu J, Pintel D, Söderlund-Venermo M.

Curr Top Microbiol Immunol. 2009;331:53-64. Review.

PMID:
19230557
17.

Expression of all six human Torque teno virus (TTV) proteins in bacteria and in insect cells, and analysis of their IgG responses.

Kakkola L, Bondén H, Hedman L, Kivi N, Moisala S, Julin J, Ylä-Liedenpohja J, Miettinen S, Kantola K, Hedman K, Söderlund-Venermo M.

Virology. 2008 Dec 20;382(2):182-9. doi: 10.1016/j.virol.2008.09.012. Epub 2008 Oct 22.

18.

VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones.

Filippone C, Zhi N, Wong S, Lu J, Kajigaya S, Gallinella G, Kakkola L, Söderlund-Venermo M, Young NS, Brown KE.

Virology. 2008 May 10;374(2):444-52. doi: 10.1016/j.virol.2008.01.002. Epub 2008 Feb 5.

19.

Construction and biological activity of a full-length molecular clone of human Torque teno virus (TTV) genotype 6.

Kakkola L, Tommiska J, Boele LC, Miettinen S, Blom T, Kekarainen T, Qiu J, Pintel D, Hoeben RC, Hedman K, Söderlund-Venermo M.

FEBS J. 2007 Sep;274(18):4719-30. Epub 2007 Aug 22.

20.

Biological and immunological relations among human parvovirus B19 genotypes 1 to 3.

Ekman A, Hokynar K, Kakkola L, Kantola K, Hedman L, Bondén H, Gessner M, Aberham C, Norja P, Miettinen S, Hedman K, Söderlund-Venermo M.

J Virol. 2007 Jul;81(13):6927-35. Epub 2007 Apr 4.

21.

Human circovirus TT virus genotype 6 expresses six proteins following transfection of a full-length clone.

Qiu J, Kakkola L, Cheng F, Ye C, Söderlund-Venermo M, Hedman K, Pintel DJ.

J Virol. 2005 May;79(10):6505-10.

22.

Genoprevalence in human tissues of TT-virus genotype 6.

Kakkola L, Kaipio N, Hokynar K, Puolakkainen P, Mattila PS, Kokkola A, Partio EK, Eis-Hübinger AM, Söderlund-Venermo M, Hedman K.

Arch Virol. 2004 Jun;149(6):1095-106. Epub 2004 Mar 25.

PMID:
15168197
23.

Cloning and sequencing of TT virus genotype 6 and expression of antigenic open reading frame 2 proteins.

Kakkola L, Hedman K, Vanrobaeys H, Hedman L, Söderlund-Venermo M.

J Gen Virol. 2002 May;83(Pt 5):979-90.

PMID:
11961251
24.

Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.

Isola J, Auvinen A, Poutiainen M, Kakkola L, Järvinen TA, Määttänen L, Stenman UH, Tammela T, Hakama M, Visakorpi T.

J Urol. 2001 May;165(5):1569-74.

PMID:
11342919
25.

Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T.

J Urol. 2000 Dec;164(6):1992-5.

PMID:
11061898
26.

Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.

Nupponen NN, Porkka K, Kakkola L, Tanner M, Persson K, Borg A, Isola J, Visakorpi T.

Am J Pathol. 1999 Jun;154(6):1777-83.

27.

Genetic alterations in hormone-refractory recurrent prostate carcinomas.

Nupponen NN, Kakkola L, Koivisto P, Visakorpi T.

Am J Pathol. 1998 Jul;153(1):141-8.

28.

Characterization of a nuclear localization signal of canine parvovirus capsid proteins.

Vihinen-Ranta M, Kakkola L, Kalela A, Vilja P, Vuento M.

Eur J Biochem. 1997 Dec 1;250(2):389-94.

29.

Intracellular route of canine parvovirus entry.

Vihinen-Ranta M, Kalela A, Mäkinen P, Kakkola L, Marjomäki V, Vuento M.

J Virol. 1998 Jan;72(1):802-6.

30.

[The use of discussion groups in the nursing care of the patient in a general hospital].

Eskola M, Kakkola L.

Sairaanh Vuosik. 1973;10:54-71. Finnish. No abstract available.

PMID:
4487766
31.

[The experimental use of discussion groups among the patients of a general hospital].

Kakkola L, Eskola M.

Sairaanh Vuosik. 1971;8:78-85. Finnish. No abstract available.

PMID:
5207354

Supplemental Content

Loading ...
Support Center